Skin Graft Market is expected to reach US$ 1,673.5 million With CAGR of 7.0% from 2021 to 2028 | B. Braun Melsungen AG, Integra Life Sciences Corporation, Smith & Nephew, AVITA Medical, MiMedx, Organogenesis Inc, Tissue Regenix Group, Zimmer Biomet, De So

According to our new research study on “Skin Graft Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Graft Thickness, Applications, Equipment, and End Users,” the market is expected to reach US$ 1,673.5 million by 2028 from US$ 985.4 million in 2020. It is estimated to grow at a CAGR of 7.0% from 2021 to 2028. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Factors such as the increasing numbers of burn injuries and rising prevalence of skin cancer and diabetes fuel the growth of the market. However, the high cost of skin grafting procedures and alternatives hinders the market growth.

Request for sample PDF Copy https://www.theinsightpartners.com/sample/TIPHE100001099/?openpr-10225

In 2020, the autologous segment accounted for the largest share of the global skin graft market. The market growth for this segment can be attributed to the wide use of autologous grafts for treating open burns and wounds. These grafts are available by prescription only, and their use is highly regulated. Therefore, the market for autologous grafts segment is expected to grow steadily during the forecast period.

B. Braun Melsungen AG, Integra Life Sciences Corporation, Smith & Nephew, AVITA Medical, MiMedx, Organogenesis Inc, Tissue Regenix Group, Zimmer Biomet, De Soutter Medical, and Nouvag AG are among the leading companies operating in the skin graft market. The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio to meet the rising demands for the skin graft. For instance, in September 2020, MiMedx Group, Inc. launched EpiCord Expandable, a latest advancement in its products portfolio. At the core of this technology is EpiCord, which has demonstrated clinical efficacy in the treatment of diabetic foot ulcers.

Market Insights

Rising Prevalence of Skin Cancer and Diabetes
Skin grafts are ideally preferred post-surgery for skin cancers. Skin grafts are generally referred for local postoperative radiotherapy (PORT) to ensure closure of surgical bed created during radiotherapy. According to Cancer Research UK, ~15,400 new melanoma skin cancer cases are registered in the UK every year, accounting for 42 new cases every day. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035. Likewise, according to the recent statistics published by the International Agency for Research on Cancer, in 2020, 19.3 million new cancer cases were registered, excluding 18.1 million for nonmelanoma skin cancer. Thus, an increase in the prevalence of skin cancer is likely to contribute to skin grafting in the coming future.

Diabetes is among the most common health conditions prevalent across the globe. According to the International Diabetes Federation’s (IDF) IDF Diabetes Atlas Ninth edition 2019, ~463 million adults were living with diabetes worldwide. The prevalence is estimated to be 700 million by 2045—nearly 79% of adults living with diabetes in low-and-middle incomes countries worldwide. Among the prevalence of diabetes, the proportion of type 2 diabetes is increasing at a much faster rate. According to the IDF, 374 million are at risk of developing type 2 diabetes in the coming future. Among diabetic patients, wound healing is prolonged, which increases the risk of skin infections if it is not healed within a particular time. ~25% of diabetic patients are likely to develop foot ulcers once in their lifetime that often need advanced diabetic wound care. Therefore, there is an increase in demand for skin grafts to treat or cover diabetic foot ulcers by eliminating the chances of contracting skin infections. Thus, the high prevalence rate of skin cancer and diabetes is expected to drive skin graft market in the near future.

The report segments global Skin Graft market as follows:

By Product

Autologous
Allogeneic
Xenogeneic
Prosthetic
Isogeneic

By Graft Thickness

Split-Thickness
Full-Thickness
Composite Graft

By Equipment

Dermatome
General Surgical Instruments
Consumables
Others

By Application

Burns
Extensive Wound
Skin Cancer
Other Applications

By End Users

Hospitals
Ambulatory Surgical Centers
Dermatology Clinics

By Geography

North America
US
Canada
Mexico
Europe
France
Germany
UK
Spain
Italy
Rest of Europe
Asia Pacific (APAC)
China
India
Japan
Australia
South Korea
Rest of APAC
Middle East & Africa (MEA)
Saudi Arabia
UAE
South Africa
Rest of MEA
South and Central America (SCAM)
Brazil
Argentina
Rest of SCAM

Purchase Copy of This Report at https://www.theinsightpartners.com/buy/TIPHE100001099/?openpr-10225

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

ABOUT US:
The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.